lundi 26 mars 2018

Onco Actu du 26 mars 2018

1. Biologie

Metastatic lymph nodes can be the source of distant metastases in mouse models of cancer [Mass. General Hospital]

3. Prévention

New calculations confirm lifestyle changes could prevent 4 in 10 cancer cases [Cancer Research UK]

More than 2,500 cancer cases a week could be avoided [Cancer Research UK]

Four in 10 cancer cases could be prevented by lifestyle changes [The Guardian]

3.1 Prévention - Tabac

Pfizer Reports Top-Line Results from a Study of CHANTIX®/CHAMPIX® (varenicline) in Adolescent Smokers [Pfizer]

Statement from FDA Commissioner Scott Gottlieb, M.D., on efforts to reduce tobacco use, especially among youth, by exploring options to address the role of flavors ‒ including menthol ‒ in tobacco products [FDA]

Pfizer's quit-smoking Chantix fails study in adolescent smokers [Reuters]

3.1.1 Prévention - Tabac - e-cigs

Cancer Research UK funded research does not support the concern that e-cigarettes are a ‘strong gateway’ into smoking [Cancer Research UK]

E-cigarettes tied to less smoking cessation [Reuters]

3.7 Prévention - Alcool

Federal Agency Courted Alcohol Industry to Fund Study on Benefits of Moderate Drinking [NY Times]

4.1 Dép., diag. & prono. - Prostate

Prostate MRI scans could help some men avoid invasive biopsy [Cacner Research UK]

PSA Screening for Prostate Cancer [Science-Based Medicine]

MRI for all men suspected of prostate cancer could save thousands of lives - new study [The Telegraph]

4.11 Dép., diag. & prono. - Ovaire

Pap Test Fluids Used In Gene-Based Screening Test for Two Gyn Cancers [Johns Hopkins]

Modified Pap tests can show early warning signs of other gynecological cancers [LA Times]

4.12 Biopsies liquides

Gene-Based Test for Urine Detects, Monitors Bladder Cancer [Johns Hopkins]

4.2 Dép., diag. & prono. - Génome

Anyone Can Now Take This Breast Cancer Gene Test, But It Probably Won’t Tell You Much [FiveThirtyEight]

4.5 Dép., diag. & prono. - Colorectal

Scottish health system quicker to spot cancer, says George Alagiah [The Guardian]

5.10 Traitements - Essais

AVEO Oncology Announces Publication of Long-term Follow-up Results from TIVO-1 Extension Study (Study 902) in TKI Refractory RCC [Aveo]

Takeda Announces Publication of Final Data from ICLUSIG® (ponatinib) Pivotal Phase 2 PACE Trial in Blood [Takeda]

Array BioPharma Announces Publication of Detailed Phase 3 COLUMBUS Trial Data of Encorafenib and Binimetinib in Melanoma Patients in The Lancet Oncology [Array]

5.12 Immunothérapies

Bacteria May Promote Pancreatic Cancer by Suppressing the Immune System [AACR]

5.12.1 Immunothérapies - partenariats

Novartis teams up with Harvard to develop next generation biomaterial systems to deliver immunotherapies [Novartis]

With major funding from Novartis, Surface Oncology launches a CD47 trial amid a swarm of rivals and files for $75M IPO [EndPoints]

5.12.3 Immunothérapies-combinaisons

Phase III IMpower150 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live longer compared to Avastin plus carboplatin and paclitaxel [Roche]

Phase III IMpower131 study showed Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer [Roche]

Leapfrogging rivals, Roche’s Tecentriq plus chemo nabs PFS endpoint in frontline lung cancer segment [EndPoints]

Roche's Tecentriq cocktail adds to lung cancer survival success [Reuters]

5.12.8 Immunothérapies - Economie

Merck's Keytruda shows up its rivals with NICE backing in bladder cancer [FiercePharma]

Another mega-startup: China investors back TCR2’s $125M cash round to fuel a preclinical assault on solid tumors [EndPoints]

5.2 Pharma

U.S. FDA Grants Priority Review for a Supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) in Non-Metastatic Castration-Resistant Prostate Cancer (CRPC) [Pfizer]

AbbVie Announces Results from Phase 2 Study Evaluating Rovalpituzumab Tesirine (Rova-T) for Third-Line Treatment of Patients with DLL3-Expressing Relapsed/Refractory Small Cell Lung Cancer [AbbVie]

Peter Thiel's Firm Backed A Biotech. Big Pharma Bought It. It Blew Up [Forbes]

AbbVie shares tank on Rova-T flop, sudden retreat from accelerated approval pitch [EndPoints]

AbbVie's lung cancer drug data disappoints; shares slump [Reuters]

5.2.1 Pharma - Partenariats

AbbVie and the International Myeloma Foundation Announce Partnership to Study the Role of a Genetic Mutation in Outcomes of Patients with Multiple Myeloma [AbbVie]

5.2.3 Pharma - économie

MorphoSys files for $150M IPO to fuel its hopeful DLBCL drug launch [EndPoints]

5.3.4 Traitements - AMM (FDA, EMA,...)

Clovis Oncology Initiates Early Access Program For Rucaparib As Treatment And As Maintenance Therapy In Recurrent Ovarian Cancer In Europe [Clovis]

Novartis drug Tasigna® approved by FDA to treat children with rare form of leukemia [Novartis]

Exelixis’ Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma [Exelixis]

Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Stage III or IV Classical Hodgkin Lymphoma [Seattle Genetics]

CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets [Clovis]

FDA expands approval of Adcetris for first-line treatment of Stage III or IV classical Hodgkin lymphoma in combination with chemotherapy [FDA]

Seattle Genetics' Hodgkin's lymphoma drug wins U.S. approval [Reuters]

FDA hands Seattle Genetics its 5th OK for Adcetris. But can they actually sell it for frontline Hodgkin lymphoma? [EdnPoints]

Abemaciclib Approval Expands Initial Treatment Options for Advanced Breast Cancer [NCI]

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 March 2018 [EMA]

EMA panel for conditional OK to Clovis's ovarian cancer drug [Reuters]

5.4 Traitements - Economie

In a boon for Roche, Novartis and more, Chinese Premier plans 'zero tariff' on imported cancer drugs [FiercePharma]

12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you [EndPoints]

5.9 AACR

Highlights from the AACR Annual Meeting [OBR]

5.9.1 AACR - sein

Acquired HER2 Mutations Confer Resistance to Hormone Therapy in ER-positive Metastatic Breast Cancer [AACR]

5.9.5 AACR - CAR-T

Improving the Effectiveness of CAR T-cell Immunotherapy [Cancer Research Catalyst]

Prior Chemotherapies May Impair Ability to Develop Effective CAR T Cells [AACR]

5.9.7 AACR - divers

Chlamydia Infection is Associated With Increased Risk of Ovarian Cancer [AACR]

6.1 Observation

Many Men with Penile Cancer Do Not Get Recommended Treatments, Study Finds [NCI]

Why does Australia have so much skin cancer? (Hint: it’s not because of an ozone hole) [The Conversation]

6.10 Politiques

Theresa May refuses to intervene over man's £54,000 NHS cancer bill [The Guardian]

6.10.1 Politiques (USA)

ASCO Commends Congress for Passing Largest NIH Funding Increase in 15 Year [ASCO]

Trump, Congress approve largest U.S. research spending increase in a decade [Science]

6.2 Implants mammaires

More Cases Are Reported of Unusual Cancer Linked to Breast Implants [NY Times]

6.5 Médecines alternatives

The deadly false hope of German cancer clinics [Science-Based Medicine]

6.6 Publications

Figures in cancer paper at root of newly failed compound called into question [Retraction Watch]

The Proposal to Lower P Value Thresholds to .005 [JAMA]

6.7 DMP, Big Data & applis

Israel to launch Big Data health project [Reuters]

6.8 Communication

How Social Media Can Reveal Overlooked Drug Reactions [NPR]